Harvard Business School and others conducted a randomized control trial (RCT) on effectiveness of eCompliance technology recently. They found that drop-out rate (or default), which leads to drug-resistance is lower by 20% (5% CI) among patients treated with eCompliance, compared to others. This was a large, rigorous RCT involving thousands of patients in four states in India, which lasted for three years. Two articles based on this research can be pursued here and here. The original research paper can be read here.
